Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq ... we successfully completed a $316 million IPO and continued to build on our track record of efficient and disciplined capital ...

after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current operating plans, Metsera estimates its existing cash and cash equivalents will ...

Additionally, Metsera is accelerating its oral formulation program for MET-097o, with outcomes anticipated in late 2025. The recent $316 million IPO will support operations through 2027 as the ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical ... we successfully completed a $316 million IPO and continued to build on our track record ...

Cash Position: Cash and cash equivalents were $588.3 million as of March 31, 2025, after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current ...

Playing Maze Mice is incredibly simple, and I highly recommend behaving as though you’re in the middle of a Pac-Man level. Now, you won’t have the fancy drift effects such as holding a ...

after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current operating plans, Metsera estimates its existing cash and cash equivalents will ...

Latest Dubai IPO gives investors an opportunity to tap into more property market growth The Dubai Residential REIT portfolio comprises some of the prime and in-demand locations in the emirate.